More than 25 companies are developing over 30 TGF-beta inhibitors, according to a pipeline assessment released by life sciences research firm DelveInsight on October 27, 2026. The drugs are being studied for conditions including anemia and several cancers.

Key Takeaways

  • DelveInsight identified more than 18 drugs in early- and mid-stage development.
  • Elritercept and OT-101 are among the therapies listed in Phase III trials.
  • Keros Therapeutics expects a $20 million payment from Takeda following the first patient’s dosing in an elritercept trial.

TGF-beta inhibitors in clinical development

TGF-beta inhibitors are designed to block a signaling pathway involved in processes including immune responses and tissue repair. Developers are investigating the drugs in oncology and other diseases, but their effectiveness and safety depend on clinical trial results.

DelveInsight’s assessment lists Takeda, Hansoh Pharma, Akeso Biopharma, EpicentRx, Sirnaomics and MedPacto among the companies developing treatments. The pipeline spans different stages and indications, so the drugs are not necessarily competing for the same patients.

ItemDetails
ElriterceptPhase III; studied for anemia and myelofibrosis.
OT-101Phase III; studied for glioblastoma.
AK130Phase II; studied for pancreatic cancer.
STP707Phase I; studied for solid tumors.

Elritercept milestone and other trials

In September 2026, Keros Therapeutics said it expected a $20 million development milestone payment under its elritercept license agreement with Takeda after the first patient was dosed in the Phase III ELRiSE MF trial. The study compares elritercept with a placebo in patients with myelofibrosis and anemia who are also receiving ruxolitinib.

Another Phase III program, OT-101, is being studied for glioblastoma. Phase II candidates include MedPacto’s vactosertib and Akeso’s AK130. In September 2025, Akeso said the first patient had been dosed in a registrational Phase II study testing AK130 with ivonescimab in previously treated pancreatic cancer.

A related acquisition

GSK completed its acquisition of Canadian clinical-stage biotechnology company 35Pharma in April 2026 for $950 million. The deal included HS235, a potential treatment for pulmonary hypertension. The company develops protein-based and TGF-beta superfamily therapies.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.